Department of Veterinary Pharmacology, The University of Tokyo, Bunkyo-ku, Tokyo 113-8657, Japan.
Gut. 2011 May;60(5):638-47. doi: 10.1136/gut.2010.227546. Epub 2010 Nov 29.
The main symptom of postoperative ileus (POI) is an intestinal motility disorder in which monocytes/macrophages and neutrophils play crucial roles. Prokinetic 5-hydroxytryptamine 4 receptor (5-HT₄R) agonists and dopamine receptor antagonists are potential therapeutic agents for directly ameliorating the motility disorder associated with POI.
To determine the effects of the 5-HT₄R agonists mosapride citrate (MOS) and CJ-033466 on intestinal smooth muscle contractility relative to immune reactions after POI.
Intestinal manipulation (IM) was applied to the rat distal ileum. Both MOS (0.3 and 1 mg/kg, s.c.) and CJ-033466 (1 mg/kg, s.c.) were administered to the animals before and after IM. At 24 h after IM, isolated intestinal smooth muscle contractile activity in vitro, gastrointestinal transit in vivo, inflammatory mediator expression and leucocyte infiltration were measured.
After IM, ileal circular muscle contractility in vitro and gastrointestinal transit in vivo were reduced and the number of macrophages and neutrophils increased in the inflamed muscle layer, resulting in the induction of inflammatory mediators such as interleukin 1 β (IL-1β), IL-6, tumour necrosis factor α (TNFα), monocyte chemoattractant protein 1 (MCP-1) and inducible nitric oxide synthase (iNOS). Both MOS and CJ-033466 significantly attenuated not only the intestinal motility dysfunction but also the leucocyte infiltration and inflammatory mediator expression after IM. The autonomic ganglionic blocker hexamethonium (1 mg/kg, i.p.) and the α7-nicotinic acetylcholine receptor (α7nAChR) antagonist methyl lycaconitine citrate (0.087 mg/kg, i.p.) blocked MOS-mediated ameliorative actions. Immunohistochemically, α7nAChR is expressed by monocytes/macrophages but not by neutrophils in the inflamed intestine.
Stimulating the 5-HT₄R accelerates acetyl choline (ACh) release from cholinergic myenteric neurons, which subsequently activates α7nAChR on activated monocytes/macrophages to inhibit their inflammatory reactions in the muscle layer. In addition to their gastroprokinetic action, 5-HT₄R agonists might serve as novel therapeutic agents for POI characterised by anti-inflammatory potency.
术后肠梗阻(POI)的主要症状是肠道蠕动障碍,其中单核细胞/巨噬细胞和中性粒细胞起着关键作用。促动力 5-羟色胺 4 受体(5-HT₄R)激动剂和多巴胺受体拮抗剂是直接改善与 POI 相关的运动障碍的潜在治疗药物。
确定 5-HT₄R 激动剂莫沙必利枸橼酸盐(MOS)和 CJ-033466 对 POI 后肠道平滑肌收缩性和免疫反应的影响。
应用肠道操作(IM)于大鼠回肠远端。在 IM 前后,MOS(0.3 和 1mg/kg,sc)和 CJ-033466(1mg/kg,sc)被给予动物。在 IM 后 24 小时,测量离体肠道平滑肌收缩活性、体内胃肠道转运、炎症介质表达和白细胞浸润。
IM 后,离体回肠环形肌收缩力和体内胃肠道转运降低,炎症肌层中巨噬细胞和中性粒细胞数量增加,导致白细胞介素 1β(IL-1β)、IL-6、肿瘤坏死因子α(TNFα)、单核细胞趋化蛋白 1(MCP-1)和诱导型一氧化氮合酶(iNOS)等炎症介质的诱导。MOS 和 CJ-033466 均显著减轻了 IM 后不仅肠道运动功能障碍,而且白细胞浸润和炎症介质表达。自主神经节阻滞剂六烃季铵(1mg/kg,ip)和α7-烟碱型乙酰胆碱受体(α7nAChR)拮抗剂甲基-lycaconitine 枸橼酸盐(0.087mg/kg,ip)阻断了 MOS 介导的改善作用。免疫组化显示,α7nAChR 表达于炎症肠道中的单核细胞/巨噬细胞,但不表达于中性粒细胞。
刺激 5-HT₄R 加速胆碱能肌间神经元释放乙酰胆碱(ACh),随后激活激活的单核细胞/巨噬细胞上的α7nAChR,抑制其在肌层中的炎症反应。除了它们的胃动力作用外,5-HT₄R 激动剂可能作为一种新型治疗药物,用于以抗炎效力为特征的 POI。